콜레라 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cholera Vaccines Market size is expected to reach USD 276.20 Million in 2034 from USD 110.36 Million (2025) growing at a CAGR of 10.73% during 2026-2034.

The cholera vaccines market is advancing as public health authorities prioritize epidemic preparedness and global immunization coverage. Future vaccines will leverage novel oral formulations, thermostable delivery systems, and adjuvant optimization to improve immunogenicity, shelf life, and ease of deployment in remote regions. Integration with digital immunization tracking platforms will enable efficient monitoring of coverage rates and outbreak management.

Emerging technologies, including recombinant vector vaccines and synthetic peptide-based formulations, promise faster production timelines and broader strain coverage. AI-driven epidemiological modeling will guide strategic vaccination campaigns, optimizing resource allocation and reducing disease incidence. Mobile health systems will facilitate community-level vaccine awareness, scheduling, and adherence tracking, supporting public health infrastructure.

Future growth will be fueled by global initiatives targeting waterborne disease prevention, improved supply chain logistics, and policy support for mass vaccination. By combining innovative vaccine technologies, digital health integration, and proactive outbreak management, cholera vaccines will play a critical role in reducing global disease burden and strengthening public health resilience.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Whole Cell v. Cholerae O1 with Recombinant B- subunit
• Killed Oral O1
• O139

By Product

• Vaxchora
• Dukoral
• Shanchol
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Other

COMPANIES PROFILED

• Valneva SE, Sanofi SA, Emergent BioSolutions Inc, PaxVax Inc, EuBiologics Co, Ltd, Shantha Biotechnics Limited, Hilleman Laboratories, Astellas Pharma Inc, Incepta Vaccine Ltd, Vabiotech
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHOLERA VACCINES MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Whole Cell v. Cholerae O1 with Recombinant B- subunit Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Killed Oral O1 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. O139 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL CHOLERA VACCINES MARKET: BY PRODUCT 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Vaxchora Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Dukoral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Shanchol Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL CHOLERA VACCINES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL CHOLERA VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Type
  • 7.2.2 By Product
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Type
  • 7.3.2 By Product
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Type
  • 7.4.2 By Product
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Type
  • 7.5.2 By Product
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Type
  • 7.6.2 By Product
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CHOLERA VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Valneva SE
  • 9.2.2 Sanofi S.A
  • 9.2.3 Emergent BioSolutions Inc
  • 9.2.4 PaxVax Inc
  • 9.2.5 EuBiologics Co.Ltd
  • 9.2.6 Shantha Biotechnics Limited
  • 9.2.7 Hilleman Laboratories
  • 9.2.8 Astellas Pharma Inc
  • 9.2.9 Incepta Vaccine Ltd
  • 9.2.10 Vabiotech